Valeant indicates Bausch plant responsible for CRL now ready to go

Valeant
Valeant says it has a new PDUFA date for the eye drug for which it was issued a complete response letter last year because of problems at the plant where it is being produced.

Valeant Pharmaceuticals International said today that it has gotten a new PDUFA date for its eye drug candidate latanoprostene bunod, indicating that Valeant thinks the Bausch + Lomb plant that will make it is ready for prime-time production. The FDA issued Valeant a complete response letter last year for the drug because of shortcomings it found at the plant.

Valeant said the FDA has set an Aug. 24 date for its decision on its NDA for latanoprostene bunod. The ophthalmic solution, which Bausch + Lomb licensed from Paris-based Nicox, can lower intraocular pressure for patients with open angle glaucoma or ocular hypertension.

Before the drug was sidelined by manufacturing problems, the beleaguered Valeant predicted it could be a billion-dollar seller. When the FDA issued the CRL in September, Valeant said the agency didn't have any efficacy issues or safety concerns about the drug candidate.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The FDA did have concerns with the Bausch plant in Tampa, Florida, where it the solution is being produced. A Form 483 shows that investigators were in the facility for nearly three weeks in February 2016. Among issues noted were problems on the filling line for ophthalmic solutions, where investigators noted on 20 occasions that plant employees investigated nonconformance readings but never got to the root of the problem so that they could prevent further incidences.

The fact that Valeant has won a new PDUFA date for the drug suggests that it has had more luck getting plant issues under control than AstraZeneca’s ZS Pharma unit. AstraZeneca announced last week that the FDA had issued a second CRL for ZS 9, a potential blockbuster treatment for hyperkalemia that was the target of AstraZeneca’s $2.7 billion buyout of ZS Pharma in 2015. It said the agency was still not satisfied with the manufacturing process being used to produce the drug.

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.